[Review] Outcome markers for clinical trials in cerebral amyloid angiopathy

[Review] Outcome markers for clinical trials in cerebral amyloid angiopathy

The Lancet Neurology

Efforts are underway for early-phase trials of candidate treatments for cerebral amyloid angiopathy, an untreatable cause of haemorrhagic stroke and vascular cognitive impairment. A major barrier to these trials is the absence of consensus on measurement of treatment effectiveness. A range of potential outcome markers for cerebral amyloid angiopathy can be measured against the ideal criteria of being clinically meaningful, closely representative of biological progression, efficient for small or short trials, reliably measurable, and cost effective.

Original Article: http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(14)70003-1/abstract?rss=yes

Julio Pereira 
www.neurocirurgiabr.com
http://www.linkedin.com/in/juliommais
http://lattes.cnpq.br/7687651239699170
Consultório (11) 3141-9550 / 3141-9553